During 2003, we continued our clinical evaluation of a topi- cal formulation of androgen for ocular surface disease. Data from the Schepens Eye Institute, Harvard Medical School, have shown that androgen deficiency is associated with dry eye and ocular surface diseases. Allergan is currently in Phase II trials with a topical treatment that may provide an effective therapy for ocular surface disease. Rounding out our leadership position in dry eye treatments is our collabo- ration with Inspire Pharmaceuticals, Inc. for diquafosol, a novel tear-stimulating agent. GLAUCOMA.  Glaucoma, the world’s second leading cause of blindness, is characterized by a slow, progressive loss of visual function related to damage of the optic nerve. Currently available glaucoma medications are approved to treat elevat- ed intraocular pressure (IOP), which is the major risk factor for this disease. LUMIGAN (bimatoprost ophthalmic solution 0.03%) is the new standard in IOP treatment for patients with open- angle glaucoma or ocular hypertension. While we continue to work on improved agents beyond LUMIGAN for lowering intraocular pressure, Allergan sees a significant need for medications that target the neurodegen- erative disorder that causes glaucoma or drugs that directly protect the optic nerve. Allergan has found in investigational laboratory studies that ALPHAGAN and other alpha-2 recep- tor agonists up-regulate cell survival, resulting in potential neuroprotection of retinal ganglion cells, the cells that die selectively in patients with glaucoma.  Allergan also is exploring neuroprotection of the retinal gan- glion cells with memantine. In laboratory studies, memantine, an antagonist of the N-methyl-D-aspartate (NMDA) type of glutamate receptor, has been shown to block glutamate’s ability to activate the NMDA receptor and protect retinal  ganglion cells from dying. We are conducting a pioneering memantine Phase III program designed to evaluate meman- tine’s ability to prevent vision loss in glaucoma patients. The program, which has enrolled more than 2,000 patients, is measuring visual function as the end point and will take sev- eral more years to complete. If proven to work, memantine, in conjunction with topical agents, would be the first and only oral medication that directly protects the optic nerve in the treatment of glaucoma. 2003 OPHTHALMOLOGY APPROVALS.  Allergan received FDA approval for three important ophthalmic medications in the past year. ZYMAR (gatifloxicin ophthalmic solution 0.3%), a fourth-generation fluoroquinolone anti-infective for bacterial conjunctivitis, was approved and launched in April 2003. ACULAR LS (ketorolac tromethamine ophthalmic solution 0.4%), a new formulation of Allergan’s leading non- steroidal anti-inflammatory drug, was approved by the FDA in May. ELESTAT (epinastine ophthalmic solution 0.5%), an  ocular antihistamine with mast cell stabilizing activity, was approved in Europe (as RELESTAT) in the first quarter and in the United States in October. In December 2003, Allergan announced that it will be co-promoting ELESTAT with Inspire Pharmaceuticals, Inc. These three medications cover a number of ophthalmic uses for front-of-the-eye diseases and continue Allergan’s strong product offering in this ophthalmology disease segment. NEUROMODULATORS.  Allergan’s strategy for its neuro- modulator research program focuses on expanding approved indications for the current product, BOTOX, and pursuing new neuromodulator-based therapeutics. Major new approvals for BOTOX in 2003 included the treatment of axillary hyper- hidrosis (excessive underarm sweating) broadly in Europe and approval for the treatment of glabellar lines (brow furrow) in France and numerous other European countries, under the trade name VISTABEL. Additionally, a Phase II investigational program for headache is being conducted at multiple centers around the world. 